Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Post by Haidukon Nov 07, 2018 1:25pm
198 Views
Post# 28938232

Skin Lightening Study – Enrolment Data

Skin Lightening Study – Enrolment Data
Assuming that the scope of the clinical trial indicates the potential product(s), it also points to the targeted market: North America.
 
Project Treatment for? Participants Duration
Skin Lightening Study Uneven Skin Tone
Facial Brown Spots
Healthy Females
Ages 25-70
12 weeks
4 visits
 
For more information: https://www.zoedraelos.com/drzoe/study/51/#main

What’s about the “Proof of Efficacy” for the Asian market (accounting for around 90% of the global skin-lightening market) or more precisely for the “skin whitener” cream (extensively advertised by SBM in the recent years)? Will it follow after having the results of this first "clinial trial" or will it be performed independently? By SBM or by the potential Asian partner?

GLTA

Haiduk

Bullboard Posts